Hi guys, Welcome to the Advanced Video Search Engine, and you are watching DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer. That video is uploaded by VJOncology at 2022-12-16T04:36:55-08:00. We are promoting this video only for entertainment and educational purpose only. So, I hope you like & enjoy it. [HRmVz6x_-kQ]
| Name | DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer |
| Video Uploader | Video From VJOncology |
| Upload Date | This Video Uploaded At 16-12-2022 12:36:55 |
| Video Discription | Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, provides an overview of the preliminary data of the Phase Ib/II DESTINY-Breast07 (NCT04538742) dose-expansion study of trastuzumab deruxtecan (T-DXd) as monotherapy or combined with pertuzumab in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer. The combination of T-DXd with pertuzumab demonstrated a manageable safety profile, although an increase in diarrhea was observed due to the addition of pertuzumab. The response rate between T-DXd as a monotherapy versus in combination with pertuzumab was not significantly different. However, the data for progression-free survival (PFS) is immature, as over ¾ of patients are still on ongoing treatment. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved. HRmVz6x_-kQ |
| Category | Education |
| Tags | Speaker: Erika Hamilton | Institution: Sarah Cannon Cancer Center | Nashville | TN | Event: SABCS 2022 | Format: Interview | Subject: Breast Cancer | Field: Trial Updates | Trial: DESTINY-Breast07 | NCT04538742 | Field: Immuno-Oncology | Field: Treatment | Medicines: Trastuzumab deruxtecan | Medicines: Pertuzumab | Medicines: Antibodies | HER2+ |
